THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU.
C4X Discovery Holdings plc
(“C4XD”, “C4X Discovery” or the “Company”)
Interim results for the six months ended 31 January 2017
27 April 2017 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, today announces its interim results for the six months ended 31 January 2017.
Strategy
Partnerships
Discovery Engine progress
Senior appointments
Dr Clive Dix, CEO of C4X Discovery, said: “The recent period has seen C4XD make significant progress towards our goal of becoming the world’s most productive, self-sustaining Drug Discovery Engine. We have strengthened our cash position and management team, and entered a strategic alliance with Evotec which, alongside our own innovative drug discovery technologies, will expand our ability to generate commercially attractive pre-clinical assets to meet the pharma industry’s increasing demand for high quality early-stage drug candidates. C4XD aims to continue growing its commercial capabilities and progressing partnering discussions with the aim of completing at least one revenue-generating deal on the C4XD portfolio in the next 12 months. Myself, the Board and senior management are excited about the future of the Company.”
Download the interim financial report below.
This website uses 'cookies' to give you the best most relevant experience. To continue you have to agree to our use of cookies policy and how and why we use cookies.
You can change which cookies are set at any time and find out more about them by reading our privacy policy.